Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

AbbVie Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term borrowings
Current portion of long-term debt and finance lease obligations
Sales rebates
Dividends payable
Accounts payable
Current portion of contingent consideration liabilities
Salaries, wages and commissions
Royalty and license arrangements
Other
Accounts payable and accrued liabilities
Current liabilities
Long-term debt and finance lease obligations, excluding current portion
Deferred income taxes
Contingent consideration liabilities
Liabilities for unrecognized tax benefits
Income taxes payable
Pension and other post-employment benefits
Other
Other long-term liabilities
Long-term liabilities
Total liabilities
Common stock, $0.01 par value
Common stock held in treasury, at cost
Additional paid-in-capital
Retained earnings (accumulated deficit)
Accumulated other comprehensive loss
Stockholders’ equity
Noncontrolling interest
Total equity
Total liabilities and equity

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. AbbVie Inc. current liabilities as a percentage of total liabilities and equity increased from 2022 to 2023 and from 2023 to 2024.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. AbbVie Inc. long-term liabilities as a percentage of total liabilities and equity decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. AbbVie Inc. total liabilities as a percentage of total liabilities and equity increased from 2022 to 2023 and from 2023 to 2024.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. AbbVie Inc. stockholders’ equity as a percentage of total liabilities and equity decreased from 2022 to 2023 and from 2023 to 2024.